Results 1 to 10 of about 197,499 (175)

Long‐acting growth hormone in 2022 [PDF]

Pediatric Investigation, 2023
After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency.
Margaret Steiner, Jacklyn Frank, Paul Saenger   +2 more
doaj   +4 more sources

Long acting growth hormone (LAGH), an update [PDF]

Frontiers in Pediatrics, 2023
In 1957, Maurice Raben at Yale was able to isolate and purify growth hormone from cadaveric pituitary glands. Pituitary growth hormone was the only way to treat children with growth hormone (GH) deficiency, until 1985 when recombinant GH became available
Margaret Steiner Grillo, Jacklyn Frank, Paul Saenger   +2 more
doaj   +4 more sources

Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs [PDF]

Frontiers in Endocrinology, 2021
Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects.
Kevin C. J. Yuen, Bradley S. Miller, Cesar L. Boguszewski, Andrew R. Hoffman   +3 more
doaj   +5 more sources

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. [PDF]

Eur J Endocrinol, 2016
Objective The Growth Hormone (GH) Research Society (GRS) convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting growth hormone preparations (LAGH).
Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen LE, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond MW, Ho K, Hoffman AR, Holly JM, Horikawa R, Höybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo X, Melmed S, Miller BS, Misra M, Popovic V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen K.   +40 more
europepmc   +13 more sources

Rationale for Long-acting Growth Hormone Therapy and Future Aspects [PDF]

JCRPE
Recombinant growth hormone (GH) is administered as daily subcutaneous injections. Daily treatment can be challenging for children/adolescents, as well as for parents and/or caregivers, such as legal representatives or guardians of children in ...
Semra Çetinkaya, Erdal Eren, Furkan Erdoğan, Feyza Darendeliler   +3 more
doaj   +6 more sources

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation [PDF]

Frontiers in Endocrinology, 2022
Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life.
Martin Bidlingmaier, Beverly M.K. Biller, David Clemmons, Jens Otto L. Jørgensen, Hiroshi Nishioka, Yutaka Takahashi, Yutaka Takahashi   +6 more
doaj   +6 more sources

Perspectives on long-acting growth hormone therapy in children and adults [PDF]

Archives of Endocrinology and Metabolism, 2020
Growth hormone therapy with daily injections of recombinant human growth hormone has been available since 1985, and is shown to be safe and effective treatment for short stature in children and for adult growth hormone deficiency. In an effort to produce
Rayhan A. Lal, Andrew R. Hoffman
doaj   +6 more sources

What do we do now that the long-acting growth hormone is here? [PDF]

Frontiers in Endocrinology, 2022
In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj   +2 more sources

RETRACTED: Effect of Weekly Long-Acting Growth Hormone Replacement Therapy Compared to Daily Growth Hormone on Children With Short Stature: A Meta-Analysis

Frontiers in Endocrinology, 2021
BackgroundWe performed a meta-analysis to evaluate the efficacy and safety of weekly long-acting growth hormone replacement therapy compared to daily growth hormone in children with short stature.MethodsA systematic literature search up to April 2021 was
Liyan Ma, Liangyi Li, Wen Pan, Congfu Huang, Limei Liu, Xiaoxiao Zhang, Xiaoxiao Zhang   +6 more
doaj   +2 more sources

Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency. [PDF]

J Endocr Soc
Abstract Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct; additional moieties or mechanisms that prolong LAGH action confer unique pharmacodynamic ...
Albers N, Cadarette S, Feakins B, Arregui M, Ebohon S, Lai P, Raveendran S, Kjelgaard-Hansen M, Andersen C, Zhao C, Smith A, Geffner M.   +11 more
europepmc   +3 more sources